|
|
|
| home > white papers > Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor - Eppendorf |
|
|
 WHITE PAPERS |
|
Eppendorf
|
|
Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor
|
|
The number of bioprocess applications for microalgae has increased in
recent years, particularly in the fi eld of biofuel production. The
combination of the New Brunswick CelliGen 310 stirred-tank bioreactor
and the DASGIP LED Illumination System creates a bioreactor setup which
is capable of supporting high density microalgal growth. Using the
stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and
intensities can be controlled for optimal support of all types of
chlorophylls and carotenoids. For this study in which high density
culture of up to 1.5 x 107 cells/mL was achieved, the unicellular
freshwater alga, Dunaliella tertiolecta, was used.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Pharmaceutical Packaging and Labelling Summit in Zurich; ACG presentation
At next week’s Pharmaceutical Packaging and Labelling Summit in Zurich (18-19 June), Dr. Eugen Hertel from ACG will be speaking on: Challenges for Global Pharma companies to Implement Anti-Counterfeit Strategy for Russian Track & Trace Regulation. This presentation will include details around ‘the fight against counterfeit medicine - there have been and still are worldwide initiatives to make the supply chain and the safety of medicines secure. After large markets such as the USA and Europe passed their laws and regulations for the pharmaceutical manufacturing companies and established the IT infrastructure, Russia is now next on the move.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models
DrugDev
For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality.
One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >> |
|
 |
Industry Events |
 |
Clinical Innovation Partnerships
11-12 September 2019, Hotel Palace, Berlin
Clinical Innovation Partnerships is the only event for senior clinical operations and
procurement professionals driving innovation in their clinical trials. It is where the
pharma, CRO and vendor clinical trials ecosystem meet to drive innovation in
digitalisation, tech and partnering to improve patient experience and reduce trial
cost and time.
More info >> |
|
|
|
